| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05829434 Details | 2024-02-12 Interventional | 2 | 0 | Cytarabine Magrolimab Myelodysplastic… Preleukemia Acute Myeloid L… Myelodysplastic… | Trial was stopped prematurely due to safety reasons - | |||
| NCT04956042 Details | 2024-02-12 Interventional | 1/2 | 18 | Cytarabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Recurrent Acute… Refractory Acut… | Discontinued - | |||
| NCT04460807 2018-000693-30 Details | 2024-02-12 Interventional | 3 | 23 | Exemestane Carcinoma, Ovar… Ovarian Neoplas… Ovarian Cancer | low accrual, COVID 19 emergency and the modification of the standard of care for ovarian cancer
treatment - | |||
| NCT05780541 Details | 2024-02-09 Interventional | 3 | 58 | Remdesivir COVID-19 | The agent was withdrawn from development by the manufacturer after being placed on clinical
hold by the US FDA. - | |||
| NCT05544565 2021-005627-21 Details | 2024-02-09 Interventional | 4 | - | Anti-Bacterial … Pyelonephritis Pyelonephritis … | Joint decision by sponsor and investigator - | |||
| NCT05308602 Details | 2024-02-09 Interventional | 2 | 0 | Vaccines COVID-19 SARS-CoV-2 Infe… | There was not a need any more. - | |||
| NCT04409223 Details | 2024-02-09 Interventional | 3 | 185 | Sunitinib Gastrointestina… | R&D strategy adjustment - | |||
| NCT04171284 Details | 2024-02-09 Interventional | 3 | 188 | Docetaxel Carcinoma, Non-… Lung Neoplasms Squamous-cell N… | Strategy adjustments, independent of the safety and efficacy of the trial medication - | |||
| NCT03493568 Details | 2024-02-09 Interventional | 3 | 100 | Dolutegravir Elvitegravir, C… HIV-1-infection | The futility analysis on 24-week results estimated that there was only 2% probability of
verifying the study hypothesis of a higher proportion pat. with no residual viremia through 48w
in arm E/C/F/TAF - | |||
| NCT03488225 Details | 2024-02-09 Interventional | 2 | 4 | Antibodies Antibodies, Mon… Antineoplastic … BB 1101 Calcium Calcium, Dietar… Cortisone Cyclophosphamid… Cytarabine Dexamethasone Dexamethasone a… Doxorubicin Folic Acid Immunoglobulins Inotuzumab Ozog… Leucovorin Levoleucovorin Liposomal doxor… Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Leukemia Leukemia, Lymph… Philadelphia Ch… Precursor Cell … Acute Lymphobla… B Acute Lymphob… B Acute Lymphob… | the study was closed early due to competing trials - | |||
| NCT03198559 Details | 2024-02-09 Interventional | 1/2 | [1 Refs] | 5 | Disulfiram Vorinostat HIV Infections | A re-evaluation of research risks to participants were greater than originally anticipated Early termination of the study lead to a small numbers of participants analyzed. Therefore there was insufficient power to measure the effect of the intervention. Other key limitations to this study include: only 2 participants received study drug; participants did not complete the full course of treatment as outlined in the study design; 1 participant missed Day 10 study medication, stopped study treatment on Day 17; 1 participant ceased study medication on Day 11; | ||
| NCT05644600 2022-003116-84 Details | 2024-02-08 Interventional | 1 | 18 | Nintedanib Healthy Subject… | The study was terminated as no drug-drug interactions were observed in Part-A of the study and
therefore Part-B of the study was not required as per protocol. - | |||
| NCT05264506 Details | 2024-02-08 Interventional | 3 | 2007 | Estradiol Contraception | Sponsor decision to stop the study early and complete all required study close-out activities.
This decision was made for business reasons unrelated to safety. None of the pre-specified
efficacy endpoints were analyzed. - | |||
| NCT04139317 2019-002660-27 Details | 2024-02-08 Interventional | 2 | 76 | Pembrolizumab Carcinoma, Non-… Lung Neoplasms Non-small Cell … | Sponsor decision to terminate due to the lack of tolerability observed in patients treated with
capmatinib and pembrolizumab in the combination arm as compared to patients treated with
pembrolizumab alone in the pembrolizumab single agent arm - | |||
| NCT02503319 Details | 2024-02-08 Interventional | 3 | 0 | Oxytocin Tranexamic Acid Hemorrhage Postpartum Hemo… | Authorization denied - | |||
| NCT02165813 Details | 2024-02-08 Interventional | 2/3 | 216 | Nitazoxanide Gastroenteritis | Continuation of enrolment was deemed not feasible due to very small eligibility numbers and
funding exhausted. - | |||
| NCT01970345 Details | 2024-02-08 Interventional | 2 | 3 | Mecasermin Autism Spectrum… Autistic Disord… Child Developme… | Decision made to terminate due to difficulty in procurement of adequate supply of treatment
drug. Decision made on April 2023 to terminate study. - | |||
| NCT04474483 Details | 2024-02-07 Interventional | 2 | 8 | Melatonin COVID-19 | difficult recruitment and complete first visit in person during thne hight of tne pandemic and
later not enough subjects - | |||
| NCT04423367 Details | 2024-02-07 Interventional | 2 | 16 | Bortezomib Dexamethasone Recurrence Red-Cell Aplasi… Acquired Pure R… | Did not meet the anticipated outcome. - | |||
| NCT04386811 Details | 2024-02-07 Interventional | 1 | 3 | Calcitriol ADHD | Following Yale University resuming in-person research activities, the investigators no longer
had dedicated funding for the study and were unable to secure additional funding to meet the
research goals. - |